Ország: Tajvan
Nyelv: kÃnai
Forrás: 衛生ç¦åˆ©éƒ¨é£Ÿå“藥物管ç†ç½² (Ministry of Health and Welfare, Food And Drug Administration)
DROSPIRENONE;;ETHINYLESTRADIOL
臺ç£æ‹œè€³è‚¡ä»½æœ‰é™å…¬å¸ 臺北市信義å€ä¿¡ç¾©è·¯5段7號53樓 (23167184)
G03AA12
膜衣éŒ
主æˆåˆ† () ; DROSPIRENONE (6832003100) MG; ETHINYLESTRADIOL (Z102100625) MG
ç›’è£
製 劑
é ˆç”±é†«å¸«è™•æ–¹ä½¿ç”¨
BAYER WEIMAR GMBH UND CO KG DOEBEREINER STR.20 D-99427 WEIMAR GERMANY DE
drospirenone and ethinylestradiol
å£æœé¿å•è—¥ã€‚
有效日期: 2026/12/24; 英文å“å: YASMIN
2001-12-24
1. 2. 2 1 3 d r o s p i r e n o n e 0.03 ethinylestradiol 3. 4. 4.1 4.2 4.2.1 4.2.2 (combined oral contraceptive)1% 21 2-3 â— () ( ) 2-5 7 â— ( ) (vaginal ring) â— (minipill ) (/IUS) minipill ( )7 â— (first-trimester) â— 4.6 21-28 7 12 12 1. 77 2. 7 - - - â— ( 2 ) 7 ( ) () â— ( 2 ) 7 1 â— 7 1. ( 2 ) 2. 7 ( ) 1 3-4Ҡ7 () 4.2.3 “ †“ †“ â€â€œâ€ 4.3 â— /( ) â— () â— (“â€) â— â— â— â— ombitasvir paritaprevir dasabuvir (DAA) (4.5â€â€) â— â— () â— () â— â— â— (venous thromboembolism VTE) VTE 1. C (APC) III(antithrombin III deficiency)CS ) 2. 3. (arterial thromboembolism ATE) ATE 1. 2. (hyperhomocysteinaemia)(antiphsopholipidantibodies) 3. (1) (2) (dyslipoproteinaemia) 4.4 (VTE) 0.03 mg ethinyl estradiolDRSP(COC) ( Yasmin) (progestins) levonorgestrel DRSP (VTE) DRSP DRSP [ (4)] (prospective 3-armed cohort study) (< 50 µg ethinylestradiol) (VTE) 8 10 /10,000 , 4.4 /10,000 2030/10,000 ethinylestradiol/ drospirenone 0.03 mg/3 mg (Yasmin)levonogestrel 3 Yasmin ( 0.03 mg EE 3 mg DRSP) levonorgestrel 1 Yasmin 023338 a) 6 b) norgestimate norethindrone levonorgestrel desogestrel norgestrel medroxyprogesterone ethynodiol diacetate c) levonorgestrel desogestrel dienogest chlormadinone acetate gestodene cyproterone acetate norgestimatenorethindrone d) norgestimate norethindrone levonorgestrel () i3 Ingenix (Seeger 2007) a EURAS (Dinger 2007) a FDA (2011) a ( ) ( ≤ 0.04 mgEE) b c Levonorgestrel/EE d Levonorgestrel/0.03 mg EE d Levonorgestrel/0.03 mg EE (HR) (95%[CI]) HR: 0.9 (0.5-1.6) HR: 0.9 (0.6-1.4) HR: 1.0 (0.6-1.8) HR: 1.8 (1.3-2.4) HR: 1.6 (1.1-2.2) HR: 1.7 (1.4-2.1) HR: 1.5 (1.2-1.8) 1Yasmin ( ) ( 1) Ingenix [Seeger 2007] EURAS ( [European Active Surveillance Study]) [Dinger 2007]EURAS (the Long-Term Active Surveillance StudyLASS) FDA ( 1) [Lidegaard 2009 Lidegaard 2011] MEGA [van Hylckama Vlieg 2009] [Dinger 2010] (Nested Case-Control Study)PharMetrics [Jick 2011] GPRD [Parkin 2011]1 1YasminLNG( # ) < 1DRSP> 1 DRSP * LNG †LASSEURAS # a) b) c) d) e) f) (BMI) g) h) i)j)k)l)m)n Olvassa el a teljes dokumentumot